Dural Sinus Stenting of Low Grade Dural Arteriovenous Fistulae (DAVF) for Pulsatile Tinnitus Treatment

Inclusion Criteria: * Patient presenting invalidating pulsatile tinnitus * Patient presenting with PT anatomically correlated with a DAVF * Type I or IIa DAVF on digital subtraction angiography (DSA), according to Cognard's classification. * DAVF located on sigmoid , lateral or posterior longitudinal sinus. * Fistula length compatible with use of up to two stents * Highly effective contraception for women of childbearing potential, maintained during research procedures * Affiliated or beneficiary of health insurance * Signed informed consent Exclusion Criteria: * Patient with DAVF not eligible for endovascular treatment . * DAVF classification of IIb or more according to Cognard's classification. * DAVF with severe sinus stenosis or occlusion judged as nor eligible for sinus stenting. * DAVF showing evidence of recent (inferior to 3 months) thrombophlebitis at the site of fistulous dural sinus. * Patient with DAVF previously treated with surgery or radiotherapy. * Patient with multiple DAVF * Controlateral sinus aplasia or occlusion * Patient presenting contra-indication to the use of LEA according to the instructions For Use. * Patient participating in another clinical study evaluating another medical device, * Any condition or any situation that would prohibit the patient from coming to the investigational center for the follow-up as recommended by the study protocol at 6 months. * Patient with any known allergy to heparin, acetylsalicylic acid, Coumadin , Warfarin or other antiplatelet medications * Patient has undergone a surgery including endovascular procedures in the last 30 days prior to the study procedure. * Patient has had an Intracranial hemorrhage and/or subarachnoid hemorrhage in the past 30 days prior to the study procedure * Known serious sensitivity to radiographic contrast agents. * Known sensitivity to nickel, titanium metals, or their alloys * Known renal failure as defined by a serum creatinine \> 2.5 mg/dl (or 220 μmol/l) or glomerular filtration rate (GFR) \< 30. * Patient who has a contraindication to MRI or angiography for whatever reason * Women who are pregnant, lactating, or who are planning to become pregnant during the anticipated study period * Patient unable to understand the nature, risks, significance and implications of the clinical investigation or unwilling to provide written informed consent * Patient under legal protection